Mounjaro / tirzepatide / tirzepatide / tirzepatide / skinny pen / tirzepatide

 

Japanese versionTirzepatideDetailed introduction to Tirzepatide and its weight loss effects

1. Introduction to Tirzepatide

Tirzepatide (brand name:Mounjarooriginally used forType 2 diabetesT2DMtreatment, is also widely used for nutritionWeight loss treatment for overweight individuals。

2. Status of the Japanese version of tirzepatide

JapanMinistry of Health, Labour and Welfare(MHLW)Approved in 2023Mounjaronot yet used for the treatment of type 2 diabetes, but not yet officially approved for weight loss. However, many doctors will, based on「IndicationFor external useOff-label use of this medication to help—off-label prescribing of this medication to non-diabetic patients helps with weight loss.

Tirzepatide and other countries (such as the Japanese version of tirzepatide and other countries (such asUnited States) version is basically identical in composition, usually adoptingSubcutaneous injectionusage, dosage, starting fromStarting from 2.5mgStart from the beginning and gradually increase to15mg(maximum dosage). The Japanese pharmaceutical market is strictly regulated, so patients usually need a doctor's prescription to obtain the drug.

3. Tirzepatide's weight loss mechanism

Tirzepatide's sustained efficacy helps significantlyWeight lossprimarily relies on the followingThe Big ThreeMechanism of action：

Reduce bottlenecks, minimize bottlenecks

• GLP-1 mechanism of action: GLP-1 can act on the brain'sHypothalamus beautyCentral nervous system, enhances satiety, and reduces appetite.
• GIPEffect: GIP can enhanceInsulin resistance, regulate energy consumption, and further reduceInsulin resistance, reducing fat storage.

✅ResultAfter using tirzepatide, patients usually feelIncreased satiety，Decreased appetite, especially a decreased appetite for high-sugar and high-fat foods.

2. Delay gastric emptying and reduce blood pressure fluctuations

• Tirzepatideimpair gastric emptying rate, keeping food in the stomach longer, therebywithout causing hunger, reduce food intake.
• can also helpstabilizing blood sugar binge eating, to prevent the rapid rises and falls in blood pressure caused bybinge eating或Hunger。

✅ResultPatients do not feel hungry very soon after eating.

3. Increase fat burning and promote lipolysis

• GLP-1 and GIPMergercan promotefat loss, decreasefat accumulation, especiallyVisceral fat。
• Research shows that GIP can also enhanceBrown adipose tissueactivity of (BAT), increaseEnergy consumptionhelp, help to alleviate.

✅Resultnot onlyReduce body fat也Improved diabetes blood sugar, reduceType 2 diabetes risk。

4.clinical researchData (SURMOUNT trials）

• • 2022The New England Journal of MedicineDisplay: A pivotal study published in (NEJM) (the SURMOUNT-1 trial) showed:
    • non-diabetic obesitypatient30（body mass index ≥30):
      • The highest dose (15 mg) resulted in an average weight loss of 20.91 TP3T over 72 weeks.(approx. 22.5 kg).
      • WeightAt least 15% of people accounted for 89%。

 

• • ComparisonSemaglutide(Wegovy 2.4mg)Cipamide'sStronger weight loss effectalternatives to cypateteStronger weight loss effect。

5. How to use Tirzepatide

• Starting dose: 2.5mg, subcutaneously once a week (usually in the abdomen, back, or upper arm).
• incremental increase(Increase every 4 weeks):
  • 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg (maximum dose).
• It is recommended to use under a doctor's guidance.Adding positions too quickly，Because adding ingredients too quickly can lead tosevere consequences。

6. Side effects of tirzepatide

Cigpeptide has significant effects, but it is still possibleGuidanceDespite the remarkable efficacy of tirzepatide, it may still cause some side effects, mainly includinggastrointestinal mismatch：

• Common consequences(usually over time):
  • Nausea (most common)
  • Hesitation
  • Diabetes or constipation
  • Bloating
• Rare but concerning consequences：
  • hypoglycemia (most common in diabetic patients treated with insulin or other glucose-lowering medications)
  • Inflammation (rarely may occur)
  • Medullary thyroid carcinoma(Animal experiments suggest a link, but human studies have not yet confirmed it)

✅Mitigation recommendations：

1. Use after mealsCan reduce gastrointestinal imbalance.
2. Avoid foods high in fat or sugar, can reduce the amount of alcohol.
3. When the dosage is increased,Drink more water and eat small, frequent mealsto adapt to the new dosage.

---

7. Compatible and incompatible people

✅Target Audience：

• 需Weight Loss ≥ 101 TP3Tobese or overweight populations (BMI ≥ 27, calculation result issue)
• patients with type 2 diabetes
• ObesityInsulin resistance, fatty liver, and polycystic ovary syndrome (PCOS)people

❌Contraindications：

• Type 1 diabetespatient
• formerly suffered fromPancreatitisor a family history of pancreatic cancerpeople
• Pregnant or breastfeeding women
• Patients with severe gastrointestinal diseases

---

8. Tirzepatide vs. Semaglutide (Wegovy/Ozempic)

Opposing item	Tirzepatide (Mounjaro)	Semaglutide (Wegovy/Ozempic)
Mechanism of action	GLP-1+G	GLP-1 onlyagonist
Weight loss effect	Up to 22% (15	Up to 161 TP3T (2.4 mg)
Appetite suppressant	強	強
EU control	EU (GIP	強
Frieren	Lighter, relatively	Oppose

✅ConclusionTirzepatide isWeight loss and blood pressure controlare superior in every aspect, but one still needs to choose based on individual circumstances.

---

9. Conclusion

• Japanese version of Tirzepatide (Mounjaro)Mainly used forType 2 diabetes treatment, but also performs prominently in weight loss.
• Food and drink，help patients manage weightnatural decrease。
• Stable weight loss results